Corporate Profile

Opthea is committed to improving vision in patients suffering from retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.

Environmental, Social & Governance

As a biotechnology innovator, Opthea recognizes the opportunity we have to drive positive outcomes for not only our own business but for the promotion of public health. Our approach to environmental, social and governance (ESG) pivots on how we intend to unite these positive outcomes with the growth of enterprise value by integrating ESG decision-making into all aspects of Opthea’s operations. Opthea has identified a range of key factors to serve as the foundation for a meaningful, purposeful, and practical ESG strategy. This has the potential to transform the way we discover and develop medical breakthroughs that will change the lives of our patients. We also understand the importance of setting measurable targets against which we can track our progress over time. This will ensure accountability to our stakeholders while enabling the business to celebrate and recalibrate as we continue to grow

Image for sustainability

Opthea Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration

event banner

Apr 3, 2024 10:00 AM EDT

Click here to register for the live webcast

Register Now